vs

Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $7.2M, roughly 1.7× GREENPOWER MOTOR Co INC.). GREENPOWER MOTOR Co INC. runs the higher net margin — -65.6% vs -1398.3%, a 1332.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -11.5%).

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GP vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.7× larger
RNA
$12.5M
$7.2M
GP
Growing faster (revenue YoY)
RNA
RNA
+445.5% gap
RNA
434.0%
-11.5%
GP
Higher net margin
GP
GP
1332.7% more per $
GP
-65.6%
-1398.3%
RNA

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
GP
GP
RNA
RNA
Revenue
$7.2M
$12.5M
Net Profit
$-4.7M
$-174.4M
Gross Margin
14.6%
Operating Margin
-1513.5%
Net Margin
-65.6%
-1398.3%
Revenue YoY
-11.5%
434.0%
Net Profit YoY
-2.1%
-117.0%
EPS (diluted)
$-0.17
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GP
GP
RNA
RNA
Q3 25
$12.5M
Q2 25
$3.8M
Q1 25
$1.6M
Q4 24
$7.2M
$3.0M
Q3 24
$5.3M
$2.3M
Q2 24
$3.0M
$2.0M
Q1 24
$3.5M
Q4 23
$8.2M
$2.2M
Net Profit
GP
GP
RNA
RNA
Q3 25
$-174.4M
Q2 25
$-157.3M
Q1 25
$-115.8M
Q4 24
$-4.7M
$-102.3M
Q3 24
$-4.7M
$-80.4M
Q2 24
$-5.4M
$-70.8M
Q1 24
$-68.9M
Q4 23
$-4.6M
$-60.4M
Gross Margin
GP
GP
RNA
RNA
Q3 25
Q2 25
Q1 25
Q4 24
14.6%
Q3 24
8.6%
Q2 24
7.4%
Q1 24
Q4 23
16.6%
Operating Margin
GP
GP
RNA
RNA
Q3 25
-1513.5%
Q2 25
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
GP
GP
RNA
RNA
Q3 25
-1398.3%
Q2 25
-4089.3%
Q1 25
-7360.0%
Q4 24
-65.6%
-3439.5%
Q3 24
-87.9%
-3441.7%
Q2 24
-179.8%
-3461.8%
Q1 24
-1943.4%
Q4 23
-56.9%
-2756.2%
EPS (diluted)
GP
GP
RNA
RNA
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.17
$-0.80
Q3 24
$-0.18
$-0.65
Q2 24
$-0.21
$-0.65
Q1 24
$-0.79
Q4 23
$-0.19
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GP
GP
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$621.1K
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1M
$1.9B
Total Assets
$37.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GP
GP
RNA
RNA
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$621.1K
$219.9M
Q3 24
$116.9K
$370.2M
Q2 24
$528.3K
$575.8M
Q1 24
$471.4M
Q4 23
$4.0M
$185.1M
Stockholders' Equity
GP
GP
RNA
RNA
Q3 25
$1.9B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$2.1M
$1.4B
Q3 24
$4.2M
$1.5B
Q2 24
$8.6M
$1.2B
Q1 24
$830.9M
Q4 23
$18.1M
$500.8M
Total Assets
GP
GP
RNA
RNA
Q3 25
$2.1B
Q2 25
$1.4B
Q1 25
$1.5B
Q4 24
$37.4M
$1.6B
Q3 24
$39.4M
$1.6B
Q2 24
$43.5M
$1.3B
Q1 24
$951.5M
Q4 23
$50.2M
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GP
GP
RNA
RNA
Operating Cash FlowLast quarter
$-1.1M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GP
GP
RNA
RNA
Q3 25
$-156.2M
Q2 25
$-199.7M
Q1 25
$-124.8M
Q4 24
$-1.1M
$-99.9M
Q3 24
$-1.3M
$-65.6M
Q2 24
$-3.2M
$-65.0M
Q1 24
$-70.4M
Q4 23
$1.4M
$16.5M
Free Cash Flow
GP
GP
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
GP
GP
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
GP
GP
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons